October 10, 2024 - by Editor Prism MarketView

iBio and AstralBio Provide Update on Myostatin Program for Obesity: Lead Molecule Identified with Potential for Extended Half-Life and Subcutaneous Dosing

10 October 2024

New York, October 10, 2024 - PRISM MarketView - iBio (NYSEA: IBIO), a company leveraging AI for precision antibody immunotherapies, announced an update on its myostatin program targeting obesity and cardiometabolic diseases in collaboration with AstralBio. The two companies have identified a lead molecule with the potential to treat muscle wasting and obesity, designed for subcutaneous dosing and with an extended half-life.

iBio, Inc. - Prism MarketView

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising

Leveraging iBio’s advanced technology, the myostatin program progressed rapidly from its inception to achieving in vitro proof-of-concept in human muscle cells. The next phase includes non-cGMP in vivo studies in rodents and non-human primates (NHP), with early NHP data expected in early 2025.

“Myostatin inhibitors hold great promise for treating obesity by increasing muscle mass and boosting metabolism. We are optimistic our novel molecule could offer an alternative to intravenous administration with less frequent dosing.”

Martin Brenner, Ph.D., DVM, iBio’s CEO and Chief Scientific Officer

The partnership with AstralBio provides iBio with an exclusive option to license three cardiometabolic targets. Should iBio choose to in-license the myostatin program, they aim to file an Investigational New Drug (IND) application by the end of 2025.

“iBio’s AI-powered platform is an innovative tool for advancing therapies that address conditions like obesity and muscle wasting. We are thrilled with the progress made on this program and look forward to advancing it further.”

Patrick Crutcher, CEO of AstralBio

About iBio, Inc.

iBio is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers, and other diseases. iBio’s mission is to decrease drug failures, shorten drug development timelines, and open up new frontiers against the most promising targets.

About PRISM MarketView:

Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.

To see this content properly accept cookies.

Disclaimer:

PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.

Contact:

PRISM MarketView
info@prismmarketview.com
646-863-6341

To see this content properly accept cookies.

Prism MarketView | Stock Market News & Investment Opportunities

To see this content properly accept cookies.